- Home
- GOAI vs UNCY Comparison
GOAI vs UNCY Comparison
Compare GOAI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$5.44
HOLD
Current Price
$6.72
Company Overview
Basic Information| Metric | GOAI | UNCY |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.9M | 141.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GOAI | UNCY |
|---|---|---|
| Price | $5.44 | $6.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 114.5K | ★ 603.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $0.45 |
| 52 Week High | $5.70 | $7.57 |
Technical Indicators
Market Signals| Indicator | GOAI | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 68.28 | 52.38 |
| Support Level | $3.95 | $5.90 |
| Resistance Level | N/A | $6.82 |
| Average True Range (ATR) | 0.71 | 0.36 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 99.64 | 59.41 |
Price Performance
Historical Comparison GOAI
UNCY
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.